VistaGen Therapeutics VTGN shares are trading higher after Baird initiated coverage on the stock with an Outperform rating and announced a price target of $9 per share.
VistaGen Therapeutics' is currently up 12.6% to a price of $2.57. The stock's volume is currently 25.34 million, which is roughly 1597.66% of its recent 30-day volume average of 1.59 million.
The stock's 50-day moving average was $2.24 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $3.18 and fallen to a low of $0.4.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
